Skip to content

Optimization and Evaluation of Diagnostic Models for Autoimmune Gastritis

Optimization and Evaluation of Diagnostic Models for Autoimmune Gastritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400092601
Enrollment
Unknown
Registered
2024-11-20
Start date
2024-11-20
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Gastritis

Interventions

Gold Standard:Endoscopic findings suggestive of reverse atrophy
?Pathological findings suggestive of reverse atrophy or ECL cell hyperplasia/ECM
?Positive PCA or IFA.
Index test:Serological indicators include six types (including pepsinogen I, pepsinogen I/II ratio, gastrin, parietal cell antibody or intrinsic factor antibody, mean corpuscular volume, serum iron, v

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients who meet the endoscopic diagnostic criteria for chronic gastritis (2022 Shanghai, China Guidelines for the Diagnosis and Treatment of Chronic Gastritis); (2) Patients who agree and are able to cooperate with the examination and all other research requirements; (3) Patients who agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with poor compliance and who cannot attend regular check-ups; (2) Patients with severe complications; (3) Patients with severe underlying diseases associated with other significant organ damage; (4) Other situations deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Serological, endoscopic, and pathological characteristics;Accuracy;Sensitivity;Specificity;

Countries

China

Contacts

Public ContactLuoHao

Beijing Hospital

602086363@qq.com+86 10 8513 2114

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026